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Patients  with  PTSD  show  deﬁcits  in  delayed  recall  and  paired  associates  learning.
Memory  deﬁcits  are  ameliorated  during  CBT.
Memory  improvement  correlates  with  the  expression  of blood  FKBP5  mRNA.
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a  b  s  t  r  a  c  t
Posttraumatic  stress  disorder  (PTSD)  is  characterized  by  hyperarousal,  ﬂashbacks,  avoidance,  and  mem-
ory dysfunctions.  Although  psychotherapy  improves  the  clinical  symptoms,  its effect  on memory  has  not
been explored.  In addition,  there  is no  information  about  gene  expression  changes  related  to  hippocam-
pal  functions.  We  assessed  PTSD  patients  (n  =  20)  using  the  Wechsler  Memory  Scale-Revised  (WAIS-R)
and  a paired  associates  learning  (PAL)  test,  as well  as  changes  in  blood  FK506  binding  protein  (FKBP5)
mRNA  expression  before  and  after  cognitive  behavioral  therapy  (CBT).  Results  revealed  that  before CBTemory
ognitive behavioral therapy
KBP5
PTSD  patients  were  impaired  on WAIS-R  delayed  recall,  attention/concentration,  and  PAL  compared  with
trauma-exposed  control  subjects  (n  =  20).  These  memory  dysfunctions  showed  a  signiﬁcant  improvement
after  CBT.  Better  performance  on the  PAL test  correlated  with  enhanced  blood  FKBP5  mRNA  expres-
sion.  These  results  suggest  that  elevated  FKBP5  expression  during CBT  is  related  to  improved  associative
memory  linked  to the hippocampal  formation.. Introduction
Posttraumatic disorder (PTSD) is characterized by signiﬁcant
voidance behavior, hyperarousal, and intrusive mental contents
ncluding thoughts, ﬂashback images, and nightmares related to
he traumatic event [1]. The pathophysiology of PTSD is unknown
lthough a role of the overactive hypothalamic-pituitary stress axis
as been suggested as one of the most important putative patho-
hysiological mechanism [2]. FKBP5 (FK506 binding protein) may
e a remarkable hub in complex molecular networks regulating the
∗ Corresponding author at: University of Szeged, Department of Physiology, Dóm
q.  10, H6720 Szeged, Hungary. Tel.: +36 20 448 3530; fax: +36 62 545 842.
E-mail addresses: keri.szabolcs.gyula@med.u-szeged.hu,
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304-3940/© 2014 Elsevier Ireland Ltd. All rights reserved.© 2014 Elsevier  Ireland  Ltd.  All  rights  reserved.
effect of the stress hormone cortisol, and evidence strongly sug-
gests its role in the pathogenesis of PTSD [3–7]. FKBP5 binds to
the cortisol receptor and reduces its afﬁnity and nuclear transloca-
tion [8]. Recently, we  found that symptomatic improvement during
cognitive–behavioral therapy (CBT) in PTSD was associated with an
increased expression of FKBP5 and an expansion of hippocampal
volume [9], which exhibits a reduced size in patients with PTSD who
display active clinical symptoms [10–12]. We  also demonstrated
a signiﬁcant positive correlation between changes in hippocampal
size and FKBP5 expression during CBT [9]. One possible explanation
is that enhanced FKBP5 expression mitigates the detrimental effect
of cortisol and consequently protects the hippocampal formation.However, the functional consequences of larger hippocampi
regarding impaired learning and memory in PTSD are unknown.
The present study was  designed to clarify this issue. We measured
memory functions and FKBP5 expression in PTSD before and after
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BT. We  hypothesized that patients with PTSD would show better
emory functions in parallel with enhanced blood FKBP5 mRNA
xpression after CBT.
. Materials and methods
.1. Participants
We  assessed 20 newly diagnosed patients with PTSD and 20
rauma-exposed non-PTSD volunteers at the early trauma inter-
ention center (National Psychiatry Center, Budapest, Hungary).
he details of the recruitment process have been described in
etails in our previous report [9]. The patients in the present
tudy comprised an independent sample and did not participate
n our previous study. None of them received psychotropic drugs.
articipants received the Structured Clinical Interview for DSM-
V axis I disorders (SCID-CV) [13], the Trauma and Life Events
elf-report Inventory (TLESI) [14], the Clinician-Administered PTSD
cale (CAPS) [15], and the Hamilton Depression Rating Scale (HAM-
) [16]. All scales were administered by trained and regularly
upervised clinicians who were blind to the aim of the study.
xclusion criteria included history of psychiatric or neurological
isorders. The control group included trauma-exposed individuals
ithout PTSD or other Axis I disorders. The demographic and clin-
cal data are presented in Table 1. The study was carried out in
ccordance with the Declaration of Helsinki and was approved by
he local ethics board. All participants gave written informed con-
ent.
.2. Procedure and CBT
At the ﬁrst assessment, patients with PTSD and trauma-
xposed controls underwent memory assessment and blood
ample drawing. After this assessment, patients with PTSD received
rauma-based CBT according to the protocol of Marks et al. [17]
for Hungarian adaptation, see [18]). CBT helps to identify, chal-
enge, and change negative automatic thoughts and maladaptive
ognitive schemas. Clinical psychologists or psychiatrists with ade-
uate training and regular supervision administered 12 weekly
.5-h sessions. The controls did not participate in any psycholog-
cal intervention. After the 12-week period, patients with PTSD
nd controls were re-assessed including memory tests and blood
ample drawing.
able 1
linical and demographic characteristics of the participants.
PTSD (n = 20) 
Age (years) 42.4 (9.6) 
Gender (male/female) 6/14 
Education (years) 11.8 (3.5) 
Type  of trauma Trafﬁc accide
Violent crime
Natural disas
Combat (n = 2
Alcohol consumption (drinks/week) 3.4 (6.1) 
Smoking (cigarettes/week) 5.5 (12.3) 
Trauma and Life Events Self-Report Inventory 5.7 (4.8) 
Duration of symptoms (months) 2.4 (3.0) 
Time since trauma (months) 9.6 (4.5) 
CAPS* Before CBT: 6
After CBT: 50
HAM-D* Before CBT: 3
After CBT: 20
ata are mean (standard deviation) with the exception of gender and trauma type. PTSD
—Hamilton Depression Rating Scale; CBT—cognitive–behavior therapy. Patients with PT
* p < 0.005 (Student’s t test, before vs. after CBT).ters 569 (2014) 116–120 117
2.3. Gene expression
The method has been described and referred in details in Yehuda
et al. [5] and in our previous study [9]. We drew fasting blood
samples between 08:00 and 09:00 h. For screening purposes, we
used Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara,
California), which was followed by qPCR for FKBP5 gene expres-
sion [5,9]. At the second assessment, we  performed only qPCR in
order to explore its possible changes after CBT. In addition to FKBP5,
we analyzed Ribosomal Protein S6 Kinase (RPS6K) (90 kDa; Affy ID:
204633 s at) RNA as a control molecule. RPS6K has been shown to
be signiﬁcantly decreased in PTSD [5] and does not change during
CBT [9]. In this study, only relative gene expression data of FKBP5
and RPS6K are reported.
2.4. Memory assessment
The Wechsler Memory Scale-Revised (WMS-R) was used to
assess memory functions [19]. The test provides 5 indices based
on 13 subtests: verbal, visual and general memory, delayed recall,
and attention/concentration. The raw data were converted to age-
corrected standard scores according to the test manual [19].
We also administered a paired associates learning (PAL) test, a
sensitive measure for hippocampal functions, modiﬁed after the
Cambridge Neuropsychological Test Automated Battery (CANTAB)
[20] and validated in different patients populations (autism and
dementias) [21]. Six objects (candies) were hidden in six candy
boxes placed in different locations on the computer screen (i-PAN4
MC,  Keith & Koep, Wuppertal, Germany). The objects had differ-
ent shape and color (circle, triangle, square, diamond, red, green,
blue, yellow, pink and brown). The boxes were opened for 3 s in a
randomized order. After this observation period, one of the objects
was presented in the middle on the screen. The task was  to touch
the box where the object was originally hidden. When the partici-
pant made a mistake, the boxes were opened again. The dependent
measure was the number of errors during the PAL test.
2.5. Data analysis
The STATISTICA 11 (StatSoft, Inc., Tulsa) software was  used for
data analysis. After ensuring that the data showed normal distri-
butions (Kolmogorov–Smirnov tests), we performed analyses of
variance (ANOVAs), Student’s t tests, and Tukey’s Honestly Signiﬁ-
cant Difference (HSD) tests. Pearson’s correlation coefﬁcients were
performed to evaluate the relationship between changes in gene
Trauma-exposed controls (n = 20)
44.0 (12.8)
8/12
12.2 (4.7)
nts (n = 7) Trafﬁc accidents (n = 9)
 (n = 8) Violent crime (n = 8)
ters (n = 3) Natural disasters (n = 2)
) Combat (n = 1)
4.4 (7.9)
4.7 (11.2)
4.3 (3.7)
–
10.4 (5.6)
5.7 (14.3) –
.0 (14.8)
0.1 (11.1) –
.0 (9.2)
—posttraumatic stress disorder; CAPS—Clinician-Administered PTSD Scale; HAM-
SD and controls did not differ in demographic measures (p > 0.1).
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Table 2
Gene expression results.
PTSD before CBT (n = 20) PTSD after CBT (n = 20) Controls at baseline (n = 20) Controls at follow-up (n = 20)
FKBP5* 0.75 (0.21) 1.06 (0.31) 1.10 (0.28) 1.12 (0.34)
RPS6K** 0.82 (0.28) 0.84 (0.33) 1.17 (0.35) 1.18 (0.37)
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aata are mean (standard deviation). PTSD—posttraumatic stress disorder; CBT—cog
* Controls > PTSD before CBT (p < 0.01, Tukey’s HSD following ANOVA).
** Controls > PTSD before and after CBT (p < 0.005, ANOVA).
xpression and memory functions. Partial correlations were calcu-
ated to control the effect of improvement in the CAPS and HAM-D
cales. The threshold of statistical signiﬁcance was   ˛ < 0.05.
. Results
.1. Gene expression
The ANOVA conducted on blood FKBP5 mRNA expression
evealed signiﬁcant main effects of group (PTSD vs. controls)
F(1,38) = 5.27, p < 0.05, 2 = 0.12, observed power: 0.61) and session
before vs. after CBT in PTSD, baseline vs. follow-up in con-
rols receiving no therapy) (F(1,38) = 22.39, p < 0.001, 2 = 0.37,
bserved power: 0.99). The two-way interaction was  signiﬁcant
F(1,38) = 9.91, p < 0.005, 2 = 0.21, observed power: 0.87).
At baseline (before CBT), patients with PTSD displayed sig-
iﬁcantly lower blood FKBP5 mRNA expression compared with
he control subjects (p = 0.006), which was not detected after CBT
p = 0.89). Patients with PTSD had signiﬁcantly increased FKBP5
xpression during CBT (p < 0.001), whereas the control subjects
howed a good test–retest consistency (p = 0.7). The data are
epicted in Table 2.
The ANOVA investigating blood RPS6K mRNA expression indi-
ated a signiﬁcant main effect of group (F(1,38) = 11.27, p < 0.005,
2 = 0.28, observed power: 0.91), but the effect of session and the
nteraction were not signiﬁcant (p > 0.3) (Table 2).
.2. PAL
The ANOVA conducted on the number of errors revealed sig-
iﬁcant main effects of group (PTSD vs. controls) (F(1,38) = 6.01,
 < 0.05, 2 = 0.14, observed power: 0.66) and session (before vs.
fter CBT in PTSD, baseline vs. follow-up in controls receiving
o therapy) (F(1,38) = 11.88, p < 0.005, 2 = 0.24, observed power:
.92). The two-way interaction was also signiﬁcant (F(1,38) = 10.12,
 < 0.005, 2 = 0.21, observed power: 0.88).
Tukey’s HSD tests indicated that before CBT patients with
TSD had more errors as compared with the performance of
he control subjects (p = 0.005), but after CBT this difference in
AL performance disappeared (p = 0.7). Patients showed a marked
mprovement during CBT (p < 0.001), whereas the performance of
he control subjects was stable (p = 0.9) (Table 3).
able 3
erformance on the WMS-R and PAL tests.
PTSD before CBT (n = 20) PTSD after CBT (n =
Attention/concentration* 88.4 (10.5) 94.3 (9.5) 
Delayed recall* 86.9 (11.6) 95.4 (12.1) 
Verbal  memory 94.3 (12.7) 96.9 (10.2) 
Visual  memory 91.5 (13.8) 93.0 (12.7) 
General memory 89.9 (14.0) 91.3 (13.9) 
PAL* 13.7 (5.9) 9.9 (4.4) 
ata are mean (standard deviation). WMS-R—Wechsler Memory Scale-Revised; PTSD
ssociates learning.
* Patients with PTSD were impaired before CBT (p < 0.05, Tukey’s HSD test following AN–behavior therapy.
3.3. WAIS-R
We  found a signiﬁcant main effect of group in the case of
attention/concentration (F(1,38) = 6.17, p < 0.05, 2 = 0.14, observed
power: 0.68), a main effect of session (F(1,38) = 10.50, p < 0.005,
2 = 0.22, observed power: 0.88), and a two-way interaction
(F(1,38) = 7.47, p < 0.05, 2 = 0.16, observed power: 0.76). Before
CBT, patients performed poorly relative to controls (p < 0.05), but
after CBT their performance was comparable to that of the con-
trol subjects (p = 0.4). The improvement during CBT was  signiﬁcant
(p < 0.005) (Table 3).
The other signiﬁcant WMS-R index was  delayed memory (main
effect of group: F(1,38) = 4.17, p < 0.05, 2 = 0.10, observed power:
0.51; main effect of session: (F(1,38) = 5.71, p < 0.05, 2 = 0.13,
observed power: 0.64; interaction: F(1,38) = 4.47, p < 0.05, 2 = 0.11,
observed power: 0.54). Before CBT, patients were impaired relative
to controls (p < 0.05), but after CBT there was no between-group
difference (p = 0.9). As expected, patients showed a signiﬁcant
improvement during CBT (p < 0.05), whereas controls did not do
so (p = 0.9) (Table 3).
In the case of visual, verbal, and general memory, there were no
signiﬁcant main effects or interactions (F < 1, p > 0.1) (Table 3).
3.4. Correlations
We  calculated three hypothesis-driven correlation coefﬁcients
between changes in FKBP5 expression and changes in PAL,
attention/concentration, and delayed recall (change: values after
CBT–values before CBT). There was a signiﬁcant relationship
between changes in blood FKBP5 mRNA and PAL (r = −0.53,
p < 0.05). The other two  correlations between FKBP5 and WMS-
R indices were not signiﬁcant (−0.1 < r < 0.1, p > 0.1). When the
changes in CAPS scores were included in a partial correlation
analysis, the results remained signiﬁcant between FKBP5 and PAL
(r = −0.48, p < 0.05), similarly to the case when changes in HAM-D
scores were controlled (r = −0.53, p < 0.05).
4. Discussion
We  found robustly increased blood FKBP5 mRNA expression
in PTSD after CBT, which is a replication of our previous ﬁndings
[9] in an independent sample. This is not a general enhancement
of gene expression because RPS6K, a widespread factor playing a
key role in the activity of ribosomes, remained unchanged [5,9].
 20) Controls at baseline (n = 20) Controls at follow-up (n = 20)
98.5 (9.8) 99.0 (10.1)
97.7 (9.1) 98.3 (14.6)
96.0 (11.5) 96.3 (11.3)
92.0 (9.5) 91.7 (10.0)
95.5 (15.4) 92.6 (14.9)
8.7 (3.8) 8.5 (3.9)
—posttraumatic stress disorder; CBT—cognitive–behavior therapy; PAL—paired-
OVA), but not after CBT.
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[C. Szabó et al. / Neuroscien
efore CBT, patients with PTSD showed impaired WMS-R delayed
ecall, attention/concentration, and PAL relative to the trauma-
xposed controls. The memory deﬁcit in PTSD was  not generalized.
emory dysfunctions in PTSD showed a remarkable ameliora-
ion after CBT, and PAL improvement was associated increased
lood FKBP5 mRNA expression. Although numerous studies have
eported impaired declarative memory in PTSD [22–26], this is the
rst study showing that CBT may  boost memory. The fact that PAL
as associated with FKBP5 expression is not surprising, assum-
ng that both are closely related to the hippocampus: PAL is a
rototypical test for hippocampal functioning [20] and enhanced
KBP5 may  be associated with the regeneration of hippocampal
etworks in PTSD [9]. In this respect, the present study has limita-
ions because we were not able to measure hippocampal volume or
ctivation in this sample. Moreover, conventional neuropsycholo-
ical tests of memory fail to show a signiﬁcant correlation with
ippocampal volume in PTSD [27], whereas tests more speciﬁcally
elated to hippocampal functions (e.g., associative learning and
cquired equivalence) may  do so [28]. This hypothesis is supported
y our results revealing a relationship between PAL and FKBP5 but
ot between WMS-R and FKBP5.
Another limitation is that the analysis was conﬁned to the
xpression of a single hypothesis-driven gene (FKBP5) with a
nown role in PTSD and a gene displaying signiﬁcant alteration
n PTSD without clear biological relevance (RPS6K) [5,9]. However,
e intended to avoid multiple comparisons because of the small
ample size, and FKBP5 is one of the most promising candidates as
 clinically relevant factor in the regulation of the hypothalamic-
ituitary stress axis and cortisol [8]. Similarly, we  did not examine
ow altered gene expression and memory functions were related
o large-scale neuronal networks implicated in the pathogenesis
f PTDS. Finally, the results must be replicated in more severely
ffected and chronic patients. We  were not able to measure FKBP5
rotein, which is a critical issue because mRNA levels do not always
orrespond with protein levels. A recent study provided evidence
or a parallel decrease of FKBP5 mRNA and protein in the amygdala
f suicide victims [29], but this relationship remains to be explored
n the peripheral blood.
FKBP5 is a regulator protein of the cortisol receptor, and abnor-
al  cortisol secretion is linked to hippocampal atrophy and poor
eclarative memory [30,31]. Therefore, it is reasonable to assume
hat boosted FKBP5 expression had a causal role in the normaliza-
ion of hippocampal function and memory improvement. Enhanced
eurogenesis, increased neuronal size, and enrichment of dendritic
rborization are the putative mechanisms of volume expansion
30,31]. However, little is known about the relationship between
lood FKBP5 and brain structure and function. We  showed a pos-
tive relationship between blood FKBP5 mRNA expression and
ippocampal volume in PTSD [9]. Others demonstrated similar
orrelations with different circulating mRNAs of glucocorticoid
eceptor-related factors (GILZ and SGK-1) in major depressive dis-
rder [32]. Although increasing evidence suggests that genetic
ariations of the FKBP5 gene have an impact on the structure and
unction of the hippocampus and amygdala e.g., [33–35], future
tudies are needed to evaluate the relationships between circulat-
ng factors (mRNA and protein) and brain structure and function.
he results of the present study must be replicated in a larger sam-
le.
. ConclusionCBT is accompanied by improved memory in PTSD, which
annot be explained by the amelioration of clinical symptoms.
ncreased expression of FKBP5, a key intracellular regulator of stress
esponse and hippocampal function, may  be critical in cognitive
[ters 569 (2014) 116–120 119
changes. These results provide a new insight into the relationship
among clinical, molecular, and cognitive features of PTSD.
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